

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Pancreatic cancer	ADAM10; amyloid precursor protein (APP)	<p>Cell culture studies suggest inhibiting ADAM10 or secreted APP could increase the efficacy of Gemzar gemcitabine in pancreatic cancer. In human pancreatic cancer cell lines, pharmacological inhibition of ADAM10, which is frequently overexpressed in pancreatic cancer, was shown to prevent the generation of secreted APP. In human pancreatic cancer cell lines, small interfering RNA against ADAM10 increased Gemzar sensitivity compared with control siRNA. Next steps include evaluating the safety and additive or synergistic effects of the combination in mouse pancreatic cancer models. Eli Lilly and Co. markets the nucleoside analog Gemzar to treat pancreatic and other cancers.</p> <p>SciBX 6(39); doi:10.1038/scibx.2013.1094 Published online Oct. 10, 2013</p>	Unpatented; licensing status not applicable	<p>Woods, N.K. & Padmanabhan, J. <i>J. Biol. Chem.</i>; published online Sept. 10, 2013; doi:10.1074/jbc.M113.459255 Contact: Jaya Padmanabhan, University of South Florida, Tampa, Fla. e-mail: jpadmana@health.usf.edu</p>